Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Next Science Ltd ( (AU:NXS) ) just unveiled an update.
Next Science Limited reported its half-year financial results for the period ending June 30, 2025, showing a 7% decline in product sales to US$10.5 million. Despite a 54% increase in direct sales of XPERIENCE, overall direct product sales fell by 20%. The company improved its operating expenses by 17%, resulting in a reduced adjusted EBITDA loss of US$2.8 million. The shareholders approved the sale of the majority of the Group’s assets to OSARTIS GmbH, expected to complete by mid-September 2025, which will not affect the company’s capital structure.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited is a medical technology company focused on commercializing its proprietary XBIO suite of products, aimed at reducing the impact of biofilm-based infections on human health.
Average Trading Volume: 558,373
Technical Sentiment Signal: Sell
Current Market Cap: A$42.43M
For detailed information about NXS stock, go to TipRanks’ Stock Analysis page.